Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of July 5, 2026, PTGX trades at $131.62 with a market cap of $8.46B and a P/E ratio of -72.72. PTGX moved +5.22% today. Year to date, PTGX is +50.84%; over the trailing twelve months it is +159.66%. Its 52-week range spans $33.31 to $131.87. Analyst consensus is strong buy with an average price target of $117.78. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for PTGX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $131.62 |
| Market Cap | $8.46B |
| P/E Ratio | -72.72 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $131.87 |
| 52-Week Low | $33.31 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $74.06M |
| Net Income | $-114.71M |
| Gross Margin | 0.00% |
10 analysts cover PTGX: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.78.